ERBB2 and breast cancer: The p110 alpha catalytic subunit was recently shown to be required for Neu-dependent mammary tumorigenesis in mice [27], arguing for selective inhibition of this PI3K p110 isoform as a potential treatment strategy for HER2-positive breast cancers.